A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
myelofibrosis
prognostic model
ruxolitinib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Oct 2023
17 Oct 2023
Historique:
received:
11
09
2023
revised:
09
10
2023
accepted:
16
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to therapy failure. As the therapeutic possibilities of MF are expanding, it is critical to identify patients predisposed to early ruxolitinib monotherapy failure and worse outcomes. We investigated predictors of early ruxolitinib discontinuation and death on therapy in 889 patients included in the "RUX-MF" retrospective study. Overall, 172 patients were alive on ruxolitinib after ≥5 years (long-term ruxolitinib, LTR), 115 patients were alive but off ruxolitinib after ≥5 yrs (short-term RUX, STR), and 123 patients died while on ruxolitinib after <5 yrs (early death on ruxolitinib, EDR). The cumulative incidence of the blast phase was similar in LTR and STR patients (
Identifiants
pubmed: 37894394
pii: cancers15205027
doi: 10.3390/cancers15205027
pmc: PMC10605705
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : RC-2023-2778976
Références
Lancet Haematol. 2020 Mar;7(3):e226-e237
pubmed: 31982039
Lancet Haematol. 2018 Feb;5(2):e73-e81
pubmed: 29275119
Future Oncol. 2022 Jun;18(20):2559-2571
pubmed: 35603634
Am J Hematol. 2020 Jun;95(6):594-603
pubmed: 32129512
Haematologica. 2015 Sep;100(9):1139-45
pubmed: 26069290
Leuk Res. 2018 Nov;74:86-88
pubmed: 30321784
Cancer. 2020 Mar 15;126(6):1243-1252
pubmed: 31860137
Blood. 2017 Aug 31;130(9):1125-1131
pubmed: 28674026
Br J Haematol. 2021 Oct;195(2):244-248
pubmed: 34331348
Blood Adv. 2022 Mar 22;6(6):1855-1864
pubmed: 35130339
Onco Targets Ther. 2013 Dec 17;7:13-21
pubmed: 24368888
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
JAMA Oncol. 2018 May 1;4(5):652-659
pubmed: 29522138
Blood. 2010 Oct 14;116(15):2857-8
pubmed: 20947690
Cancer. 2022 Jul 1;128(13):2420-2432
pubmed: 35499819
Lancet Haematol. 2017 Jul;4(7):e317-e324
pubmed: 28602585
JAMA Oncol. 2015 Aug;1(5):643-51
pubmed: 26181658
Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):415-421
pubmed: 32199764
Blood. 2013 Aug 22;122(8):1395-8
pubmed: 23838352
Br J Haematol. 2018 May;181(3):397-400
pubmed: 28419426
J Clin Oncol. 2017 Dec 1;35(34):3844-3850
pubmed: 28930494
Cancer. 2023 Jun 1;129(11):1704-1713
pubmed: 36932983
Lancet. 2023 Jan 28;401(10373):269-280
pubmed: 36709073
Leuk Lymphoma. 2023 Jun;64(6):1063-1081
pubmed: 37081809
Oncotarget. 2017 Jun 27;8(45):79073-79086
pubmed: 29108288
Leukemia. 2017 Dec;31(12):2726-2731
pubmed: 28561069
Blood Cancer J. 2022 Aug 12;12(8):116
pubmed: 35961958
Ann Hematol. 2022 Jan;101(1):131-137
pubmed: 34625831
Blood Adv. 2022 Jan 25;6(2):373-375
pubmed: 34753179